Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients
- 1 August 2015
- journal article
- research article
- Published by Elsevier BV in Burns
- Vol. 41 (5), 956-968
- https://doi.org/10.1016/j.burns.2015.01.001
Abstract
No abstract availableThis publication has 36 references indexed in Scilit:
- Spectrum and drug resistance of pathogens from patients with burnsBurns, 2012
- Yakult: a role in combating multi-drug resistant Pseudomonas aeruginosa?Journal of Wound Care, 2012
- Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactamsCritical Care, 2011
- Mortality and causes of death in a burn centreBurns, 2008
- Pharmacokinetic variability of extended interval tobramycin in burn patientsBurns, 2008
- Population pharmacokinetics of arbekacin in burn patientsEuropean Journal of Clinical Pharmacology, 2008
- Influence of Burns on Pharmacokinetics and Pharmacodynamics of Drugs Used in the Care of Burn PatientsClinical Pharmacokinetics, 2008
- Outcome measures in burn care: Is mortality dead?Burns, 2004
- Objective Estimates of the Incidence and Consequences of Multiple Organ Dysfunction and Sepsis after Burn TraumaThe Journal of Trauma and Acute Care Surgery, 2001
- Predicting Outcomes of BurnsThe New England Journal of Medicine, 1998